154 related articles for article (PubMed ID: 38124737)
1. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
[TBL] [Abstract][Full Text] [Related]
3. Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study.
Yin C; Zou GR; He Y; Li J; Yan HW; Su Z; Cao XL; Li XB
J Thorac Dis; 2023 Apr; 15(4):1838-1847. PubMed ID: 37197501
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.
Wang S; Liang Q; Chi Y; Zhuo M; An T; Duan J; Wang Z; Wang Y; Zhong J; Yang X; Chen H; Wang J; Zhao J
Thorac Cancer; 2020 May; 11(5):1149-1159. PubMed ID: 32162417
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV).
Xu CR; Chen Q; Zhou C; Wu L; Li W; Zhang H; Li Y; Xu F; Xiong J; Wang Q; Zhang H; Jiang Y; Yin H; Wu Q; Dai Q; Hu J; Chen J; Zhang J; Wu G; Yin J; Zhao J; Liu B; Shan J; Sheng L; Chen Q; Han Z; Shi H; Liu Y; Chen J; Wu YL
Transl Lung Cancer Res; 2023 Jan; 12(1):127-140. PubMed ID: 36762057
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
[TBL] [Abstract][Full Text] [Related]
9. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
[TBL] [Abstract][Full Text] [Related]
10. Camrelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: Treatment response, survival pattern, and safety.
Cao H; Wei W; Lu Y
J Clin Pharm Ther; 2022 Nov; 47(11):1775-1782. PubMed ID: 35851702
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer.
Kotake M; Kuwako T; Imai H; Tomizawa Y; Kaira K; Yoshii A; Ochiai M; Miura Y; Osaki T; Sakurai R; Takei K; Minato K; Saito R
Chemotherapy; 2020; 65(1-2):21-28. PubMed ID: 32674095
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of camrelizumab combined with chemotherapy in nonsquamous nonsmall cell lung cancer as the second-line therapy: A retrospective analysis.
Huang W; Zhang Q; Da L; Shen Y; Xiong F; Zhang C
J Cancer Res Ther; 2022 Apr; 18(2):576-580. PubMed ID: 35645130
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q; Wang XY; Jiang RC; Ba Y; Li K
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma.
Xin D; Song Y; Mu L; Zhang B; Qi L; Gao J; Wang X; Xu J; Qu T; Huang J
Thorac Cancer; 2023 May; 14(15):1392-1397. PubMed ID: 37035870
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.
Sonoda T; Umeda Y; Demura Y; Tada T; Nakashima K; Anzai M; Yamaguchi M; Shimada A; Ohi M; Honjo C; Waseda Y; Akai M; Ishizuka T
Cancer Med; 2023 Jun; 12(12):13041-13053. PubMed ID: 37081729
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer].
Zheng X; Wang H; Zhang G; Yan X; Ma Z
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):513-518. PubMed ID: 30037370
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
Ren S; Wang X; Han BH; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38388167
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.
Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y
Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]